Recruiting

SGLT2i

Sponsor:

Yale University

Code:

NCT05612594

Conditions

Sleep Apnea

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Bexagliflozin 20 mg

Placebo

Study Details

Brief summary:

The goal of this clinical trial is to test if bexagliflozin lowers the sleep apnea severity in adults who are overweight or obese with moderate to severe obstructive sleep apnea (OSA) compared with a placebo (look-alike substance that contains no active drug).

The main question it aims to answer is:

  • If SGLT2i will reduce anatomic and physiologic traits, clinical measures of OSA and sleep deficiency in participants
  • If improvement in clinical measures are because of improvement in the anatomic and physiologic traits.

Participants will be placed on either drug or placebo and get routine normal care for 6 months. At the start and end of the study, participants will undergo different clinical measurements to see if the drug makes the sleep apnea better.

Conditions

Sleep Apnea

Study ID

NCT05612594

Start date

Mar 27, 2024

Status verified date

Aug, 2026

Completion date

Sep, 2027

Anticipated

Primary completion date

Sep, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Able to provide informed consent and stated willingness to comply with all study procedures and availability for the duration of the study
  • Overweight or obese (body mass index 25-40 kg/m2)
  • Clinically confirmed diagnosis of obstructive sleep apnea by one of the following methods:

a. Polysomnography: AHI ≥15/hour sleep or b. Home sleep apnea testing: Respiratory event index (REI) ≥15/hour sleep
  • AHI: apnea-hypopnea index (apneas + hypopneas / total sleep time in hours)

Exclusion Criteria:

An individual who meets any of the following criteria will be excluded from participation in this study:

  • Known non-OSA related conditions associated with sleep disordered breathing (e.g., central disorder of hypersomnolence, neurological, neuromuscular, or pulmonary disorder)
  • Use of sleep-inducing medications (e.g. benzodiazepines, opiates, barbiturates)
  • Type 1 diabetes mellitus
  • History of diabetic ketoacidosis
  • Known hypersensitivity reaction to bexagliflozin or any of its constituents or any contraindication to bexagliflozin use
  • Severe, recurrent urinary tract or genital mycotic infections
  • eGFR<30mL/min/1.73m2 at time of or within 4 weeks of enrollment in the study
  • Unable to complete/tolerate magnetic resonance imaging (MRI) due to severe claustrophobia or metallic implants.
  • Language barrier, mental incapacity, unwillingness or inability to understand.
  • Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant.
  • Currently or planning to take a SGLT2i prior to or during enrollment in the study
  • Currently or planning to follow a ketogenic diet pattern ("keto diet) prior to or during enrollment in the study
  • Currently or planning to follow an active weight loss program (including but not limited to use of supplements, medications, or surgery) prior to or during enrollment in the study
  • Currently or planning to follow an intermittent fasting diet plan prior to or during enrollment in the study
  • Currently or planning to take a GLP-1 receptor agonist prior to or during enrollment in the study .
  • Existing lower limb ulcer (due to diabetes or any cause)
  • Existing severe peripheral arterial disease with intermittent claudication and/or prior lower limb revascularization procedure
  • Concomitant administration of UGT inducers
  • Severe liver disease

Study Design

Enrollment

164 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Bexagliflozin

Bexagliflozin once daily for 6 months

placebo comparator: Placebo

Placebo once daily for 6 months

Interventions

Bexagliflozin 20 mg

15mg once daily

Placebo

matching placebo once daily

Primary outcome measure

  • Change in Apnea hypopnea index (AHI) measured by full ambulatory polysomnography (aPSG) [ Time Frame: Baseline and 6 months ]

Central Contacts and Locations

Central contacts

Henry K Yaggi, M.D.

203-785-4163henry.yaggi@yale.edu

Ian J Neeland, M.D.

216-844-5965Ian.Neeland@UHhospitals.org

Locations

Yale New Haven Health

Recruiting

New Haven, Connecticut, United States, 06520

University Hospitals Cleveland Medical Center

Recruiting

Cleveland, Ohio, United States, 44106

More Information

Sponsor

Yale University

Last update posted

Aug 27, 2026

Last verified

Aug, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-06. This information was provided to ClinicalTrials.gov by Yale University on 2026-08-27.